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Acronyms 
ART = Antiretroviral therapy 
PopART = Population Effects of Antiretroviral Therapy to Reduce HIV Transmission 
HBT = home-based voluntary testing 
HPTN = HIV Prevention Trials Network 
HPTN 071 = The HPTN study number for the PopART intervention 
CD4 = CD4+ cell count per μL of peripheral blood  
PMTCT = prevention of mother to child transmission of HIV 
 
Notations 
In the following,  
A1 is the indicator function, with value 1A =1  if A  is true and 0  otherwise. 
( )moda k is the remainder of the Euclidian division of a  by k . 
2013.5startt =  is the date of start of the intervention. 
 
Model structure 
The model is a deterministic compartmental model describing the population aged 15 years 
and over, specified by a system of ordinary differential equations for the time-evolution of the 
number of individuals in different states. The time unit is the year. 
 
Individuals are stratified according to sex (female/male), infection status 
(susceptible/infected), and sexual risk propensity (high/medium/low).  
 
Susceptible males are classified as uncircumcised, uncircumcised waiting for circumcision, 
circumcised in healing period, or circumcised. Adult susceptible males who get circumcised 
go through each of those compartments sequentially. Susceptible males who are circumcised 
before the age of 15 enter directly the circumcised compartment. The proportion of men 
circumcised during adolescence ( 76%birthmc =  in the Western Cape region of South Africa, 
13% in Zambia) in each country was taken from data from the ZAMSTAR trial [1,2]. Males 
can be infected in any of these stages.  
 
Infected individuals are classified as untreated, untreated waiting for treatment, treated but not 
virally suppressed, and treated and virally suppressed. Untreated individuals who engage into 
treatment go through these compartments sequentially. Those in the two later stages can drop 
out of treatment, coming back to the untreated compartment.  
 
Infected individuals are further classified in one of five disease stages: the first one is the 
early (or acute) stage, followed by one of four stages, defined by the CD4 level (Stage 1 
corresponds to CD4≥500, stage 2 to 350≤CD4<500, stage 3 to 200≤CD4<350, and stage 4 to 
CD4<200). Whilst for untreated individuals, the CD4 count referred to in this classification is 
the actual CD4 count of individuals, for those on ART, it refers to the CD4 count individuals 
would drop to should they interrupt treatment. The model of progression between these stages 
was matched to reflect a recent re-analysis of clinical cohort data [3] (see next section, Figure 
2b and Table S 4).  
 
Notations for the different compartments are described in Tables S 1 to S 3. The full flow 
diagram between the different compartments is shown in Figures S 1 (males) and S 2 
(females).  
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Table S 1. “Social” characteristics 
Characteristic Notation Detail 
Sex a  a f= : female 
a m= : male 
We define  if  and  if  
Circumcision 
status 
(for males 
only) 
x  x u= : uncircumcised 
x p= : uncircumcised planning circumcision 
x h= : circumcised healing 
x c= : circumcised 
Sexual 
behaviour 
i  1i = : high sexual activity 
2i = : moderate sexual activity 
3i = : low sexual activity 
Localisation * Individuals living in neighbouring areas from the trial 
communities are indicated with a * 
  
Table S 2. Infection stages 
Characteristic Notation Detail 
Infection stage k  1k = : CD4≥500 
2k = : 350≤CD4<500.  
3k = : 200≤CD4<350 
4k = : CD4<200 
The acute infection is modelled by a separate state variable. 
For untreated individuals, the CD4 count referred to in this 
classification is the actual CD4 count of individuals; for those 
on ART, it refers to the CD4 count individuals would drop to 
should they interrupt treatment. 
  
Table S 3. State variables. State variables represent the number of individuals in each state at 
different times during the epidemic. There are 288 state variables in total. Social 
characteristics are shown in subscripts ( a , x  and i  refer to sex, circumcision status, and 
sexual behaviour respectively (see Table S1)). Infection stages are shown in superscripts ( k , 
see Table S2). Individuals living in neighbouring areas from the trial communities are 
indicated with a *. 
State variable Notation 
Susceptible (uninfected). 
 in the trial community;  
*
axiS  in neighbouring areas 
Infected, acute infection. 
mhiP ; ; 
*
mhiP  ;
*
aiP  
Untreated chronic infection ; *kaiI  
Untreated chronic infection waiting for treatment k
aiJ  ; 
*k
aiJ  
Treated chronic infection, not virally suppressed k
aiT  ; 
*k
aiT  
Treated chronic infection, virally suppressed ; *kaiA  
 
 
a f= a m= a m= a f=
axiS
aiP
k
aiI
k
aiA
3  
 
Figure S 1: Flow diagram for men in risk group i in the trial cluster. Other risk groups and neighbouring communities have similar flow diagrams. Arrows pointing to 
bottom left represent non-HIV related mortality. 
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 Figure S 2: Flow diagram for women in risk group i in the trial cluster. Other risk groups and neighbouring communities have similar flow diagrams. Arrows pointing to 
bottom left represent non-HIV related mortality.
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Parameterizing disease progression 
 
Upon becoming infected, all individuals first enter the acute infection stage, lasting for a 
mean of 0.24 years [4]. Following acute infection, individuals may enter any of the CD4 
stages CD4 >500, CD4 350-500, CD4 200-350, and CD4 ≤200, and individuals progress to 
the next lowest stage at a constant rate. Individuals in the stage CD4 ≤200 experience HIV-
related mortality. Parameters determining the proportion entering each CD4 cell count stage, 
piinitCD4, i = 1,…,4, and the progression rate between each stage, ρ i, i = 1,…,3,  were estimated 
by least-squares to obtain the closest fit to the percentage in each CD4 category annually for 
the first six years after seroconversion in recent model estimates based on European 
seroconverter cohorts (Figure 1 in [3]).  The rate of HIV-related mortality for those with CD4 
<200, ρ4, was chosen to get an incidence of 35.2 deaths per 100 per year amongst those 
individuals [5]: ( )4 ln 1 0.352 0.434ρ = − − = , leading to a mean survival from infection to 
death of 12.0 years (median 10.4 years).  
 
For treated individuals, the model does not attempt to describe CD4 cell dynamics.  Instead, 
the model captures in a simple stylised manner two important processes: the mortality of 
patients on ART and the CD4 level to which individuals drop when they interrupt treatment, 
which both depend mainly on the nadir CD4 count immediately prior to the initiation of ART 
and the time since ART initiation [6-10]. Here, we do not attempt to fit this part of our model 
to data. Instead, we use a similar simple assumption to Granich et al. [11], specifically that 
treated patients progress through nadir CD4 count categories at a rate kσ  which is half that of 
untreated patients.  
 
Parameters relating to disease progression are summarized in Table S 4. 
 
Table S 4. Clinical progression parameters. Subscript k  shows the CD4 stage (see Table S 2). 
Description Symbol Value Ref 
Rate of progression 
from acute to chronic 
infection  (year-1) 
 4.14 (corresponding to mean 
duration of 2.9 months)
 
[4] 
Rates of progression 
to the next chronic 
infection stage   
(year-1) 
 
  
1
1 0.157
6.37
ρ = =  
2
1 0.350
2.86
ρ = =  
3
1 0.282
3.54
ρ = =
 
4
1 0.434
2.30
ρ = =  
1,...,3k = :  
Fitted to data from [3] 
 
4k = : adapted from [5]  
 
Note that the mean survival time 
cannot be obtained from these 
alone since after primary infection 
individuals can directly enter low 
CD4 compartments. 
Proportion starting in 
each CD4 class after 
acute infection 
4ini
k
tCDp  
  
4
2 0.23
initCDp =  
4
3 0.16
initCDp =  
4
4 0.03
initCDp =  
Fitted to data from [3] 
Rates of disease 
progression when 
under treatment  
(year-1) 
kσ  0.5k kσ ρ=  
[11] – see explanations for this 
counterintuitive assumption in the 
main text. 
 
In a sensitivity analysis, we explored the impact of the intervention under the extreme 
scenario where 0kσ = , that is, individuals on ART experience no HIV-related mortality, and 
pρ
kρ
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when they interrupt treatment, they return to the CD4 count they were at immediately before 
initiating treatment. The corresponding relative reduction in 3-year cumulative HIV incidence 
was 59% in arm A in both countries and 27% (Zambia) and 26% (South Africa) in arm B, 
compared to arm C. These results are very similar to those obtained in the main scenario we 
considered ( 0.5k kσ ρ= ), which confirms that the model of survival and CD4 cell dynamics 
on ART will not dramatically affect the short term projections. Interestingly, the 10-year 
projections were also relatively similar in both scenarios (60% (arm A) and 30 to 32% (arm 
B) reduction in 10-year cumulative HIV incidence in the scenario with 0kσ = , compared to 
64% (arm A) and 29% to 31% (arm B) in the scenario with 0.5k kσ ρ= ). 
 
 
Modelling testing, treatment and circumcision 
 
We model separately a background process of HIV-related care, representing the current 
patterns of uptake of testing, treatment and circumcision services, and an additional process 
resulting from the intervention activities in the trial. Therefore the rates describing 
engagement into care are defined as the sum of a background term, and, for arms A and B and 
during the trial, an additional term describing the intervention. More precisely: 
 
 
 
 
Background testing, treatment and circumcision 
Background (i.e., not linked to the trial) treatment programmes (recruitment and drop-out) 
were adapted from Granich et al [11]. Background HIV testing is not modelled explicitly. 
Instead, we model the rate at which individuals initiate ART, which encompasses both testing 
and successful linkage to care. We assume that only individuals with CD4<350 can initiate 
treatment. The rate at which they do so is modelled as a Hill function increasing from 2004 
onwards, with a greater rate for individuals with CD4<200.  
More precisely, the rates at which untreated infected individuals enter the “awaiting for 
treatment” compartment is (depending on the CD4 category):  
 
 
 
 
That is, prior to the trial as well as in arm C during the trial, there is no treatment initiation 
from CD4≥500 (τ1) and CD4 350-500 (τ2) stages, and individuals with CD4<200 link to ART 
at twice the rate of individuals with CD4 200-350 (τ4 = 2τ3) to allow for a faster treatment rate 
for individuals with CD4<200. The value of maxτ  was constrained so that the total proportion on 
treatment in year 2010 matches data from the ZAMSTAR trial [1,2]; values for Zambia and South 
Africa were 0.513 and 0.305 year-1 respectively.  
 
Regarding circumcision, we assume that, in all arms and both countries, a certain proportion 
of males are circumcised prior to entry into the modelled population at age 15. We assume 7  
these are fully circumcised. We do not model any adult circumcision outside of that offered as 
part of the intervention package in arms A and B:  
.
 
 
 Additional testing, treatment and circumcision in arms A and B during the trial 
In addition to this background process, during the trial, community HIV-care providers 
(CHiPs) teams will offer, in arms A and B, home-based testing every year during 6-months 
rounds in the intervention arms of the trial. These intervention rounds are scheduled to last 6 
months: here we model these taking place from 1st July to 31st December, from 2013 to 2015. 
These annual rounds of testing are modelled by a constant number of tests offered each day 
during those time periods by CHiPs.  
 
Following testing by CHIPS (which, when offered, is only accepted by a proportion testp  of 
individuals), a fraction circp  of susceptible men who have accepted testing will decide to get 
circumcised and a fraction ARTp  of infected individuals who have accepted testing will decide 
to get treated.  
 
Parameterization of the rate of HIV testing by CHiPs was not straightforward since, generally 
speaking, a constant flow out of a compartment X (here, a compartment of individuals who 
receive HIV testing), of size , cannot be modelled by a constant rate 
 
(here, rate of 
HIV testing). To get a constant flow, the rate has to be parameterized as  
so that the flow is constant:  (t0 being an arbitrary date). This 
parameterization leads to a linear decrease in . However, if there are other routes out of 
the compartment X (such as infection, migrations, deaths), this can lead to negative value of
. In our model, this reflects for instance the fact that individuals who have died (or 
initiated treatment outside of the trial context) before the CHiPs rounds will not be offered a 
test.  
 
 Therefore the rate has to be multiplied by the proportion of those expected to be in X at time t 
who are actually still in compartment X at time t:  
, which simplifies to . 
 
Therefore, overall, the rate of susceptible men entering the waiting circumcision stage is: 
 
and the rate of untreated infected individuals entering the waiting for treatment stage is: 
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with ;  D = 0.5 year the duration of the CHiPs rounds 
each year;   equals 1 when t is during the last six months of each calendar 
year (where the intervention takes place) and zero during the rest of the year; and 
 the time since the start of the latest round of intervention. 
 
 
Individuals who accept testing and circumcision or treatment then enter the “waiting” stages 
before actually getting circumcised, at a rate circτ or treated at a rate 
k
ARTτ dependent on 
disease stage k . 1k
ARTτ
reflects the average time from testing to ART initiation. In arm A, this 
encompasses the time for individuals to show up at a clinic, get a CD4 test, and start 
treatment irrespective of CD4 count: , with  
waitν  the average time between HIV testing and treatment initiation, which encompasses the 
delays between testing and visit to the clinic, the delay between visit to the clinic and CD4 
test results, and the delay between CD4 test results and actual ART initiation when eligible. 
In arms B and C (as well as before the intervention and in the neighbouring communities), 
this additionally accounts for the fact that non-eligible individuals will not start treatment: 
( ) ( ) ( ) ( ) ( )
1 2 3 4 10;ART ART ART ART
wait
t t t t
t
τ τ τ τ
ν
= = = = . 
 
With this parameterization, in arm B, individuals who are tested at high CD4 counts remain in 
the “waiting treatment” stage until they reach CD4<350, after which they initiate treatment at 
a rate , that is on average after 4 weeks. However, these individuals have 
to come back for repeated CD4 counts before finding out they are eligible for treatment. But a 
large proportion of patients do not come back for these tests [12], and if they do, it is at a 
much lower rate than individuals coming for their first CD4 count (national recommendation 
for pre-ART monitoring in Zambia and South Africa is once every 3 or 6 months depending 
on current CD4 count). To account for this effect, we assumed that in fact these individuals 
remained in the untreated compartments until they reached CD4<350 and were 
then revisited by CHiPS teams (i.e. ).  They 
could then enter the “waiting treatment” stage at a rate  (k=3 or 4).  
 
Once circumcised, adult males go through a healing period that lasts on average 
1
healτ  
after 
which they are healed and circumcised. Similarly, after ART initiation individuals first enter a 
phase where they are not virally suppressed, which lasts on average
suppr
1
τ
after which they are 
finally virally suppressed. 
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Treatment failure and drop-out 
Individuals on ART can drop out (or have treatment failure). They are then assumed to go 
back to the “untreated” stage. They may then be re-started on ART at a later time. The rates 
of recruitment into care are the same for individuals who are recruited for the first time and 
others. We assume a fixed annual drop-out rate 0ϕ , which can be expressed as
1
0
0 1 e 1 e
dtϕ
ϕϕ
−
−
∫
= − = − , where ϕ is the instantaneous drop-out rate. Therefore 
( )0ln 1ϕ ϕ= − − . In a sensitivity analysis, we allow the annual drop-out rate to change to a 
new value  in the communities receiving the intervention. The corresponding 
instantaneous drop-out rate is then calculated with a similar formula.  
 
Parameters related to testing, circumcision and treatment are described in Table S 5. 
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Table S 5. Model parameters related to testing, circumcision and treatment.  
Description Symbol Value Ref 
Testing and circumcision combined    
 Rate of testing and deciding to get 
circumcised  
   
 Background rate of testing and deciding to 
get circumcised  
 0  
 Intervention-related rate of testing and 
deciding to get circumcised  
  For explanations on this ratio see page 8. 
Testing and treatment combined    
 Rate of testing and deciding to get treated    
 Background rate of testing and deciding to 
get treated 
  
 
 
 
 Intervention-related rate of testing and 
deciding to get treated 
 
 
For explanations on this ratio see page 8. 
 Maximum background rate of testing and 
deciding to get treated (year-1) 
 0.513 (Zambia)   
0.305  (south Africa)  
Fitted to data from the ZAMSTAR trial 
[1,2]   
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Testing alone    
 Probability of accepting HIV test if offered 
by CHiPs test
p
 0.837 
(central target) 
[13,14] 
 Duration of CHiPs rounds (year) D 0.5 year Corresponds to 6 months 
Circumcision    
 Probability of getting circumcised given 
negative HIV test deliverd by CHiPs circ
p   0.5circp =  
(central target) 
 
 Rate of getting circumcised once decision 
to get circumcised has been made (year-1) circ
τ    
26circτ =  
(central target) 
corresponds to an average time to get 
circumcised of 2 weeks 
 Rate of circumcision healing (year-1) 
healτ   26healτ =  corresponding to an average healing period of two weeks[15] 
Treatment    
 Probability of going to get treatment given 
a positive HIV test deliverd by CHiPs ART
p   0.837 (central target)
 [13] 
 Rate of treatment initiation after testing 
and deciding to get tested  
( ) ( )
( ) ( ) ( )
( ) ( ) ( )
1 2
3 4
3 4
0 (before trial and during trial in arms B and C)
1  (during trial in arm A)
1  (all arms)
ART ART
ART ART
wait
ART ART
wait
t t
t t
t
t t
t
τ τ
τ τ
ν
τ τ
ν
= =
= =
= =
  
 Mean time between positive test and 
treatment initiation when eligible (year) wait
ν  1
13  (central target) 
=4 weeks 
 Rate of viral suppression for individuals on 
ART (year-1) suppr
τ  supprτ =8
 
Corresponds to a mean time to 
suppression of 1.5 months, based on [16] 
 Annual drop-out rate when no intervention 
0ϕ    
 
 Annual drop-out rate with intervention 
  (central target) 
 
 Instantaneous drop-out rate    in absence of intervention
 
 in presence of intervention 
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Contact patterns, relative susceptibility and relative infectivity 
 
We use a model of assortative heterosexual sexual mixing between three sexual risk groups.  
The risk groups are defined by decreasing rates of partner change: 1 2 31 0.1cc c> = > = . The 
proportion if  of the population in each group i  is fitted. We assume partnerships are made 
preferentially within the same risk group, with a level of assortativity θ  which is calibrated to 
fit prevalence estimates [17]. We further assume that within a partnership, unprotected sexual 
acts occur at an instantaneous rate which depends on the risk groups of the two individuals: it 
is the same for all partnerships between individuals of different risk groups, as well as 
partnerships between two mid-risk individuals; it is twice higher for partnerships between two 
high-risk individuals ( 1 2ψ = ) and twice lower for partnerships between two low-risk 
individuals ( 3 0.5ψ = ) [18]. 
To allow for contamination, we assumed that 5%π =  (in the central target scenario) of 
partnerships are formed with partners from outside the study community. This value is varied 
in sensitivity analyses.  
Parameters relating to risk groups and contacts are shown in Table S 6. 
 
Table S 6. Parameters relating to risk groups and contacts. Subscript  shows the risk group (see 
Table S 1). 
Description Symbol Value 
Rate of partner change 
  is fitted (see Table S7)  
 
Proportion in each risk group 
 
Fitted (see Table S7) 
Assortativity 
 
Fitted (see Table S7) 
Relative rate of unprotected sexual acts within same-risk 
group partnerships1  1
2ψ =   
 
Proportion of sexual acts with partners outside of the 
community  
5%π =  (central target) 
1relative to partnerships between individuals of different risk groups 
 
Susceptibility is assumed to be decreased by circumcision, and infectivity to be greater during 
early/acute and late stage infection, and reduced in individuals on ART (but less so for non- 
virally suppressed individuals). Men in the wound healing period after circumcision are 
assumed to have a decreased sexual activity, but an increased susceptibility per sex act, 
leading to an overall reduced susceptibility. Similarly, if infected during the healing period, 
men are assumed to be more infectious until the end of the healing period, but accounting for 
their decreased sexual activity, they are overall less infectious.  
 
In a sensitivity analysis, we also investigate the possibility that individuals in the “waiting” 
stages benefit from the HIV counselling delivered with the test and therefore reduce their 
unprotected sexual activity, resulting in lower susceptibility and infectivity levels. We also 
allow possible changes in behaviours at the community level (i.e., in both infected and 
uninfected individuals) associated with the intervention leading to an overall change in the 
sexual contact rate by a factor .bci  13  
Parameters relating to relative susceptibility and infectivity are shown in Table S 7. Relative 
susceptibility and infectivity of different stages are also summarised in Figure 1b and Figure 
2c. 
 
Table S 7. Susceptibility and infectivity of different stages. Subscript k  shows the CD4 stage (see 
Table S 2). 
Description Symbol Value Ref 
Basic transmission rate, defined as the rate at 
which an untreated infected individual with 
CD4≥350 not in acute infection transmits to a 
partner, assuming they are both in the mid-risk 
group 
 
Fitted (see Table 
S7) 
 
Relative infectivity1 of    
 Acute infection 
 
26.04   adapted from [4]  
 Each chronic infection stage 
 1 2 3
1i i i= = =  
4 2.34i =  
adapted from [4] 
 
 Infected men in circumcision healing 
period heal
i
 
3.5 0.11 0.385× =  [19,20] 
 Individuals waiting treatment 
pARTi  
1 (central target)  
 Individuals on ART not virally suppressed 
0ARTi  0.5  
 Individuals on ART virally suppressed 
ARTi  0.1  (central target) 
[21] 
 All infected individuals due to behavioural 
changes associated with the intervention 
bci  1 (central target)  
Relative susceptibility2 of    
 Circumcised men 
mcs  0.4 [22-25] 
 Men in circumcision healing period 
heals  
3 0.11 0.33× =  [20] 
 Men waiting circumcision 
pcircs  
1 (central target)  
1relative to uncircumcised untreated males with 200≤CD4<500, 2 relative to uncircumcised males 
 
 
Demography 
 
In order to realistically describe the demographic dynamics in each country, we used time 
varying per-adult birth rates ( )tβ and adult population sizes ( )N t  taken from the literature 
(passed and future projections, see below) as inputs to the model (where adults are defined as 
individuals aged over 15).  
The non-HIV related death rate ( )tµ  was calculated dynamically so that the population size 
resulting from the model would match that from the literature:  
  
with   year (corresponding to half a week) the time step of resolution of the system 
of differential equations. 
 
We assumed that the projected birth rates and population sizes taken from the literature 
represented projections under a scenario without interventions (i.e. arm C). We run the model 
pi
14  
under this scenario, and calculated the corresponding death rates. These death rates were then 
used as inputs for simulations run with interventions (i.e., arms A and B). This way, we 
assumed the same birth and death rates for all scenarios, but allowed varying population sizes 
according to the different scenarios. As a result, the population size in arm C was that taken 
from the literature, and the population sizes in arms A and B were larger because of reduced 
HIV-related deaths.  
 
The adult population sizes ( )N t  and per capita birth rate  from mid-1978 onwards 
were taken from http://www.un.org/esa/population/. The per capita birth rates were then 
divided by a constant κ  representing the proportion of adults in the population (  for 
Zambia and  for South Africa, same source) to obtain the per-adult birth rates 
.  
 
The rate of sexual maturation was assumed a fixed 15 years, and we neglected child 
mortality, so that the rate of new entrants into the sexually active class was number of births 
15 years ago. We assumed half of births were of each sex. 
 
Demographic parameters are shown in Table S 8. 
 
Table S 8. Demographic parameters. 
Description Symbol Value Ref 
Per-adult birth rate1 ( )tβ    
Per capita birth rate  
 
 http://www.un.org/esa/
population/ 
Proportion of adults in the 
population1  
 (Zambia) and 
  (South Africa)  
http://www.un.org/esa/
population/ 
Non HIV-related death rate ( )tµ  
Calculated so that model run 
in arm C produces 
population sizes consistent 
with projections from 
literature 
 
Total adult population size1 ( )N t  
 http://www.un.org/esa/
population/ 
1adults defined as aged 15 and over.  
 
 
Equations for the trial clusters 
 
The following system of differential equations describes the dynamics of the number of 
individuals in each state: susceptible (1), acute infection (2), chronic/untreated infection (3), 
infected/waiting for treatment (4), infected/treated but not virally suppressed (5) and 
infected/treated and virally suppressed (6). State variables are defined in Table S 3 and 
parameters in Table S 4 to S 8. The epidemic in the cluster and in the neighbouring 
communities is seeded with 0.01% of the population, all males in acute infection, allocated to 
the three risk groups proportionally to their size. The time  of seeding is fitted. 
 
 
 
κ
κ
κ
κ
0t
15  
 where  and  are the forces of infections applied to males and females in risk 
group i (see below).  
( )
( ) ( )( ) 2
( )
mhi
mi mhi mhi
mi
mi mui pcirc mpi mc mci mhi p mi
fi
fi fi p fi
heal heal
heal
dP FOI S P
dt
dP FOI S s S s S P P
dt
dP
FOI S P
dt
s µ
µ ρ
µ ρ
τ
τ
 = + 
 
 = + + + 

−
+ −
−

 
= +  
 
( )
( )
( )
4
4
1
1
1
1
1 1 1 1
1( )
3
( )  for 2,3 4 ,
initCD
initCD
ai
p ai test ai ai ai
kai
p ai ai tes
k
k k k k
k k k t ai ai ai
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A proportion π  of sex acts takes place with individuals from neighbouring areas in which the 
epidemic is simulated using the same model without the intervention (i.e. parameters for 
those are as in Arm C). Moreover, a proportion  of sexual contacts are assumed to be 
formed assortatively—with members of the same sexual risk group—while the remaining 
, are selected at random. Therefore the force of infection can be written as: 
 
θ
1 θ−
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In the formula above, the s are the sum of all infected individuals of sex a and risk group 
j, weighted by their current transmission potential (accounting for relative infectivity of 
different stages), and rate of partner change, which depends on whether contact is assortative 
or not. For random mixing, partnerships are considered to be of intermediate length, that is on 
average   . We also account for the fact that individuals can change partners or move to a 
different stage of infection before infecting their current partner: therefore we consider the 
relative likelihood of infection compared to other possible events, which explains the ratios in 
the equations below (see [4,26] for detail):  
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,  
 
with 0λ λ=  before the intervention and in arm C, and 0 bciλ λ=  in arms A and B during the 
intervention (  is the basic transmission rate, defined as the rate at which an untreated 
infected individual with CD4≥350 not in acute infection transmits to a partner, assuming they 
are both in the mid-risk group), and with the following population sizes, of adult males and 
females, stratified by risk group: 
, 
, 
 , , . 
 
Equations for the neighbouring communities 
 
The equations governing the epidemic dynamics in the neighbouring communities are very 
similar, but with: 
 
, with similar formulas for *ai
randK and *assortaiK  as 
for dai
ranK  and assortaiK and with population sizes calculated as for the clusters..  
 
Model calibration 
 
The model was calibrated to national HIV prevalence curves as reported by UNAIDS [27]. 
More precisely, the parameter values shown in Table S 9 were chosen to minimize the mean 
squared relative error between annual prevalence predicted by the model and UNAIDS 
prevalence estimates from 1990 to 2007. The fits for both countries are shown in Figure 3. 
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Table S 9. Fitted parameters. The model was calibrated to UNAIDS prevalence estimates for each 
country (see Figure 3).  
Description Name Fitted Value (South Africa) 
Fitted Value 
(Zambia) 
Time of epidemic seeding  1979.50 1981.26 
Basic transmission rate, defined as the 
rate at which an untreated infected 
individual with CD4≥350 not in acute 
infection transmits to a partner, 
assuming they are both in the mid-risk 
group 
0λ  0.23 0.39 
Proportion in high risk group  0.23 0.18 
Proportion in mid risk group  0.30 0.22 
Partner change rate in high risk group 
(year-1)  1.83 2.03 
Assortativity of mixing  0.87 0.90 
 
Sensitivity analysis 
 
• Influence of parameter calibrated to prevalence curves 
We assessed whether the set of parameter values chosen to match UNAIDS prevalence 
estimates had a large impact on the predicted reduction in HIV incidence. To do so, we 
explored, using a Latin hypercube sampling scheme, a range of parameter values for the 
parameters described in Table S 9. We selected the 9 parameter sets (out of 9000) with best 
fits to the prevalence. For each of these, we then ran an optimization routine, starting from 
this parameter set, to obtain a neighbour parameter set with an even better fit to HIV 
prevalence. We compared the predicted reduction in incidence under these 9 final parameter 
sets to the original best-fit parameter combination. The 10 parameter sets are shown in Figure 
S 3 and S 4, and the corresponding fits and predicted HIV incidence and prevalence in Figure 
S 5. The relative reduction in HIV incidence in intervention arms compared to the control 
arms are shown in Figure S 6.  
 
0t
highf
midf
highc
θ
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Figure S 3. Ten parameter sets calibrated to the UNAIDS prevalence estimates for Zambia. The red 
dots show the best fit parameter set. 
 
Figure S 4. Ten parameter sets calibrated to the UNAIDS prevalence estimates for South Africa. The 
red dots show the best fit parameter set. 
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Figure S 5. Ten model fit and corresponding projections under central target scenario for Zambia 
(top row) and South Africa (bottom row). Left panels show HIV prevalence and right panels show 
HIV annual incidence. The red, blue and black lines correspond to arms A, B and C respectively. The 
grey dots and error bars are the UNAIDS prevalence estimates [27]. 
 
 
Figure S 6. Projected impact of the intervention on HIV incidence in Arms A and B compared with 
Arm C for central target scenario in Zambia (top row) and South Africa (bottom row), under 10 
parameter sets calibrated to the UNAIDS prevalence estimates.  The red dots show the best fit 
parameter set. 
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• Influence of process parameters 
We explored the sensitivity of the main outcome (3-year cumulative HIV incidence) on 
process parameters (shown in Table 2) to anticipate which of those would need to be 
monitored most closely as they are most likely to influence the success of the trial. We 
defined a best-case and a worse-case value for each parameter (see Table S 10) during the 
intervention in arms A and B (assuming that before the intervention and in the control arm 
parameter values would be the “central target” ones, see Table S 10). For each country, we 
generated, using a Latin hypercube sampling scheme, a set of 1000 parameters drawn 
uniformly in those ranges and examined the resulting variability in the predicted 3-year 
cumulative HIV incidence in each arm. 
We used a linear model to explore the relationship between the 3-year cumulative HIV 
incidence (on the natural scale) and the process parameters:  
 
0 1 2 3 4 5
7 8 9 10 11
ART bc test ART UTT
circ pART pcirc circ wait
i i p p
p i s
χ χ χ χ χ χ ϕ
χ χ χ χ τ χ υ ε
∆ = + + + + +
+ + + + + +
 
 
where  is the relative reduction in incidence (in either arm A or arm B compared to arm C), 
the s are the coefficients of the regression, reported in Table 2, and ε  is the error term. 
 
The relative importance of each predictor was quantified by its contribution to the total 
variance. This was computed using the method described in [28], which performs a 
decomposition of the total variance that accounts for correlation between predictors.  
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Table S 10. Model parameters in four scenarios with various degrees of optimism 
Parameter Name 
Most 
pessimistic 
target 
Central 
target 
Optimistic 
target 
Most 
optimistic 
target 
Ref 
Proportion of sex acts with 
individuals from 
neighbouring areas 
π  0.1 0.05 0.05 0.0 
 
Relative infectivity due to 
behavioural changes bc
i  1.33 1.0 1.0 0.67  
Annual drop-out rate after 
intervention has started UTTϕ  0.2 0.1 0.1 0.01 
 
Efficacy of ART in 
blocking transmission 
during intervention 
ARTi  0.2 0.1 0.05 0.01 
[21] 
Rate of getting circumcised 
once decision to get 
circumcised has been made 
(year-1) 
circτ  
6 (average 
delay from 
test to 
circumcision: 
2 months) 
26 
(average 
delay 2 
weeks) 
52 (average 
delay 1 
week) 
182.5 
(average 
delay 2 
days) 
 
Probability of going to get 
treatment given a positive 
HIV test delivered by 
CHiPs 
ARTp  0.7 0.837 0.867 0.95 
[13] 
Probability of getting 
circumcised given negative 
HIV test delivered by 
CHiPs 
circp  0.25 0.5 0.5 0.75 
 
Probability of accepting 
HIV test when offered by 
CHiPs 
testp  0.6 0.837 0.867 0.95 
[13,14] 
Relative infectivity of 
individuals waiting 
treatment 
pARTi  1 1 1 0.8 
Based 
on [29] 
Relative susceptibility of 
individuals waiting 
circumcision  
pcircs  1 1 1 0.8 
Based 
on [29] 
Mean time between 
positive test and actual start 
of treatment (year) 
waitυ  2
13    8365   
 
 
• Influence of the time period over which the intervention is carried out 
each year 
We simulated the intervention in arms A and B assuming that the intervention would be 
carried out over 6 months, 9 months or 12 months every year. We found that the relative 
reduction in cumulative 3-year incidence would be greater if the intervention was carried out 
over 6 months rather than 9 or 12 (see Figure S 7). 
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Figure S 7. Projected impact of the intervention on HIV incidence in Arms A and B compared with 
Arm C for central target scenario in Zambia (top row) and South Africa (bottom row), assuming the 
intervention is carried out over 6 months (red), 9 months (green) or 12 months (purple) every year.  
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